Phase 2 Relapsed or Refractory Clinical Trials
31 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 31 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 2
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Hodgkin LymphomaRelapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center257 enrolled10 locationsNCT03618550
Recruiting
Phase 1Phase 2
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.166 enrolled10 locationsNCT07116616
Recruiting
Phase 2
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute52 enrolled2 locationsNCT06660368
Recruiting
Phase 2
Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu30 enrolled1 locationNCT07489989
Recruiting
Phase 2
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
MCLRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Peking University Third Hospital43 enrolled1 locationNCT07460362
Recruiting
Phase 1Phase 2
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Relapsed or Refractory Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS122 enrolled32 locationsNCT05300282
Recruiting
Phase 2
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Shandong New Time Pharmaceutical Co., LTD90 enrolled1 locationNCT07312188
Recruiting
Phase 2
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Mantle Cell LymphomaMarginal Zone LymphomaRelapsed or Refractory B-cell Non-Hodgkin Lymphoma
University of Utah27 enrolled1 locationNCT06300528
Recruiting
Phase 2
Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
Relapsed or Refractory Large B-cell Lymphoma
University of Utah29 enrolled1 locationNCT06788964
Recruiting
Phase 2
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.160 enrolled1 locationNCT07018050
Recruiting
Phase 1Phase 2
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Zhejiang ACEA Pharmaceutical Co. Ltd.84 enrolled4 locationsNCT05565807
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Phase 2
Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
Relapsed or Refractory Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China25 enrolled1 locationNCT06996132
Recruiting
Phase 1Phase 2
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL
Natural Killer/T-cell LymphomaRelapsed or Refractory Lymphoma Including ENKL
Fudan University68 enrolled1 locationNCT06966154
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb85 enrolled40 locationsNCT06035497
Recruiting
Phase 2
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Relapsed or Refractory Acute Myeloid Leukemia (AML)
Tarapeutics Science Inc.18 enrolled1 locationNCT05241093
Recruiting
Phase 1Phase 2
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)
Chengdu Zenitar Biomedical Technology Co., Ltd144 enrolled1 locationNCT06484829
Recruiting
Phase 2
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Relapsed or Refractory Peripheral T-cell Lymphoma
Great Novel Therapeutics Biotech & Medicals Corporation33 enrolled5 locationsNCT05833724
Recruiting
Phase 1Phase 2
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Relapsed or Refractory B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences20 enrolled1 locationNCT06834529